Clinical efficacy and safety of high-dose imatinib for chronic myeloid leukemia patients: An updated meta-analysis

被引:9
作者
Liu, Yonghua [1 ]
Fang, Bingmu [1 ]
Jiang, Jinhong [1 ]
Wang, Peng [2 ]
机构
[1] Wenzhou Med Univ, Affiliated Hosp 6, Dept Hematol, Lishui 323000, Zhejiang, Peoples R China
[2] Wenzhou Med Univ, Affiliated Hosp 6, Dept Clin Lab, Lishui 323000, Zhejiang, Peoples R China
关键词
Chronic myeloid leukemia; complete cytogenetic response; imatinib; meta-analysis; 800; MG; PHASE-III; MULTICENTER; INTERFERON; MANAGEMENT;
D O I
10.4103/0973-1482.191623
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: The aim of this study was to evaluate the clinical efficacy and safety of high-dose imatinib (IM) for chronic myeloid leukemia (CML) patients by pooled published studies. Methods: Through searching the databases of PubMed, EMBASE, ASCO, ESMO, CNKI, and Wanfang, we collected open published clinical controlled trials-related high-dose IM treatment of CML. The pooled complete cytogenetic response (CCyR) and hematologic toxicities were calculated by the statistical software. Results: Seven studies were included in this study with 1137 cases received high-dose IM treatment and 958 cases received regular-dose IM treatment. The pooled results showed that patients received high-dose IM had higher CCyR compared with regular-dose with the odds ratio (OR) of 1.75 (95% confidence interval [95% CI]: 1.44u2.1, P < 0.05) and 1.58 (95% CI: 1.38u1.81, P < 0.05) in 6 and 12 months. However, the hematologic toxicities risk of neutropenia (OR = 1.76, 95% CI: 1.22u2.54) and thrombopenia (OR = 1.88, 95% CI: 1.42u2.50) were much higher in the high-dose group. Conclusion: High-dose IM for CML treatment was superior to standard-dose IM in the aspects of CCyR, but the risk of developing neutropenia and thrombopenia was much higher.
引用
收藏
页码:23 / 26
页数:4
相关论文
共 16 条
  • [1] [Anonymous], WORLD LATEST MED INF
  • [2] Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study
    Baccarani, Michele
    Rosti, Gianantonio
    Castagnetti, Fausto
    Haznedaroglu, Ibrahim
    Porkka, Kimmo
    Abruzzese, Elisabetta
    Alimena, Giuliana
    Ehrencrona, Hans
    Hjorth-Hansen, Henrik
    Kairisto, Veli
    Levato, Luciano
    Martinelli, Giovanni
    Nagler, Arnon
    Nielsen, Johan Lanng
    Ozbek, Ugur
    Palandri, Francesca
    Palmieri, Fausto
    Pane, Fabrizio
    Rege-Cambrin, Giovanna
    Russo, Domenico
    Specchia, Giorgina
    Testoni, Nicoletta
    Weiss-Bjerrum, Ole
    Saglio, Giuseppe
    Simonsson, Bengt
    [J]. BLOOD, 2009, 113 (19) : 4497 - 4504
  • [3] Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study
    Cortes, Jorge E.
    Baccarani, Michele
    Guilhot, Francois
    Druker, Brian J.
    Branford, Susan
    Kim, Dong-Wook
    Pane, Fabrizio
    Pasquini, Ricardo
    Goldberg, Stuart L.
    Kalaycio, Matt
    Moiraghi, Beatriz
    Rowe, Jacob M.
    Tothova, Elena
    De Souza, Carmino
    Rudoltz, Marc
    Yu, Richard
    Krahnke, Tillmann
    Kantarjian, Hagop M.
    Radich, Jerald P.
    Hughes, Timothy P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (03) : 424 - 430
  • [4] Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia
    Deininger, Michael W.
    Kopecky, Kenneth J.
    Radich, Jerald P.
    Kamel-Reid, Suzanne
    Stock, Wendy
    Paietta, Elisabeth
    Emanuel, Peter D.
    Tallman, Martin
    Wadleigh, Martha
    Larson, Richard A.
    Lipton, Jeffrey H.
    Slovak, Marilyn L.
    Appelbaum, Frederick R.
    Druker, Brian J.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2014, 164 (02) : 223 - 232
  • [5] METAANALYSIS IN CLINICAL-TRIALS
    DERSIMONIAN, R
    LAIRD, N
    [J]. CONTROLLED CLINICAL TRIALS, 1986, 7 (03): : 177 - 188
  • [6] Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib
    Gambacorti-Passerini, Carlo
    Antolini, Laura
    Mahon, Francois-Xavier
    Guilhot, Francois
    Deininger, Michael
    Fava, Carmen
    Nagler, Arnon
    Della Casa, Chiara Maria
    Morra, Enrica
    Abruzzese, Elisabetta
    D'Emilio, Anna
    Stagno, Fabio
    le Coutre, Philipp
    Hurtado-Monroy, Rafael
    Santini, Valeria
    Martino, Bruno
    Pane, Fabrizio
    Piccin, Andrea
    Giraldo, Pilar
    Assouline, Sarit
    Durosinmi, Muheez A.
    Leeksma, Onno
    Pogliani, Enrico Maria
    Puttini, Miriam
    Jang, Eunjung
    Reiffers, Josy
    Valsecchi, Maria Grazia
    Kim, Dong-Wook
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (07): : 553 - 561
  • [7] Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia
    Hehlmann, Ruediger
    Lauseker, Michael
    Jung-Munkwitz, Susanne
    Leitner, Armin
    Mueller, Martin C.
    Pletsch, Nadine
    Proetel, Ulrike
    Haferlach, Claudia
    Schlegelberger, Brigitte
    Balleisen, Leopold
    Haenel, Mathias
    Pfirrmann, Markus
    Krause, Stefan W.
    Nerl, Christoph
    Pralle, Hans
    Gratwohl, Alois
    Hossfeld, Dieter K.
    Hasford, Joerg
    Hochhaus, Andreas
    Saussele, Susanne
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (12) : 1634 - 1642
  • [8] Measuring inconsistency in meta-analyses
    Higgins, JPT
    Thompson, SG
    Deeks, JJ
    Altman, DG
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2003, 327 (7414): : 557 - 560
  • [9] Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)
    Hughes, Timothy P.
    Hochhaus, Andreas
    Branford, Susan
    Mueller, Martin C.
    Kaeda, Jaspal S.
    Foroni, Letizia
    Druker, Brian J.
    Guilhot, Francois
    Larson, Richard A.
    O'Brien, Stephen G.
    Rudoltz, Marc S.
    Mone, Manisha
    Wehrle, Elisabeth
    Modur, Vijay
    Goldman, John M.
    Radich, Jerald P.
    [J]. BLOOD, 2010, 116 (19) : 3758 - 3765
  • [10] Discovery of the Philadelphia chromosome: a personal perspective
    Nowell, Peter C.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (08) : 2033 - 2035